0001104659-21-023428.txt : 20210216
0001104659-21-023428.hdr.sgml : 20210216
20210216120748
ACCESSION NUMBER: 0001104659-21-023428
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210212
FILED AS OF DATE: 20210216
DATE AS OF CHANGE: 20210216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oren Dan
CENTRAL INDEX KEY: 0001636701
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 21634766
MAIL ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 30600000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dexcel Pharma Technologies Ltd.
CENTRAL INDEX KEY: 0001720007
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 21634767
BUSINESS ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 3060000
BUSINESS PHONE: 97246364040
MAIL ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 3060000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001006281
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 650643773
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 SNUNIT ST
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 2161401
BUSINESS PHONE: 972-4-988-9488
MAIL ADDRESS:
STREET 1: 2 SNUNIT ST
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 2161401
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHODONTIX INC
DATE OF NAME CHANGE: 19980422
FORMER COMPANY:
FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP
DATE OF NAME CHANGE: 19960124
3
1
tm216121d3_3.xml
OWNERSHIP DOCUMENT
X0206
3
2021-02-12
0
0001006281
Protalix BioTherapeutics, Inc.
PLX
0001720007
Dexcel Pharma Technologies Ltd.
10 HAKIDMA STREET
YOKNEAM
L3
2069200
ISRAEL
0
0
1
0
0001636701
Oren Dan
1 DEXCEL STREET
OR AKIVA
L3
3060000
ISRAEL
0
0
1
0
Common Stock
4556031
D
Common Stock Purchase Warrants
2.36
2020-03-11
2025-03-11
Common Stock
2816901
D
The warrants contain a blocker that prohibits the holder from exercising the warrants if such exercise will result in beneficial ownership of more the 9.99% of the Issuer's outstanding common shares by the warrantholder and its affiliates. Since the reporting persons' beneficial ownership percentage is over 9.99%, the warrants are currently not exercisable.
/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman
2021-02-16
/s/ Dan Oren
2021-02-16